Vir Biotechnology, Inc.·4

Mar 8, 11:35 AM ET

Friedl-Naderer Johanna 4

4 · Vir Biotechnology, Inc. · Filed Mar 8, 2022

Insider Transaction Report

Form 4
Period: 2022-03-02
Friedl-Naderer Johanna
Chief Business Officer, Global
Transactions
  • Award

    Common Stock

    2022-03-02+90,00090,000 total
  • Award

    Stock Option (Right to Buy)

    2022-03-02+45,00045,000 total
    Exercise: $24.13Exp: 2032-03-01Common Stock (45,000 underlying)
Footnotes (2)
  • [F1]Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
  • [F2]25% of the shares subject to the stock option vest and become exercisable on March 2, 2023, and the remainder vest in 36 equal monthly installments thereafter.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION